GLP-1s Before Surgery: Current Guidance and What to Ask

Tell your procedural team early if you take semaglutide, tirzepatide, or another GLP-1 medicine. Most patients do not automatically need to stop treatment before an elective procedure under current U.S. multisociety guidance, but your anesthesiologist, procedural clinician, and prescriber need to agree on the plan.¹

This is not a medication-hold calendar. The procedure, type of anesthesia, symptoms, treatment stage, and reasons for taking the drug all matter. Instructions from an old online article should not replace your team's current directions.

Why the stomach matters during anesthesia

GLP-1 medicines can delay gastric emptying. If stomach contents enter the lungs during general anesthesia or deep sedation, aspiration can be serious. Zepbound and Wegovy labels describe rare postmarketing reports despite patients following preoperative fasting instructions.²³

The labels also state that available data are insufficient to determine whether changing fasting or temporarily stopping treatment reduces the risk. They instruct patients to tell health professionals about planned procedures. That limitation explains why a safety warning can coexist with individualized professional guidance rather than one proven stopping interval.

A person with persistent vomiting, marked fullness, or other concerning digestive symptoms needs assessment. Our gastroparesis guide explains why those symptoms cannot be diagnosed from a medication list alone.

Why you may have received different advice before

ASA's June 2023 consensus suggested holding daily products on the procedure day and weekly products for a week before elective procedures. It was based on limited evidence, including case reports.⁴ That historical advice still circulates in search results and copied patient instructions.

The October 2024 multisociety guidance changed the general approach: most patients can continue, with assessment of patient-specific risk and coordination among the treating teams.¹ ASA's patient guidance reviewed in October 2025 continues to describe this individualized approach.⁵

This does not mean every facility must give identical instructions or that a clinician-directed pause is always inappropriate. It means a blanket “everyone must stop for a week” should not be represented as the sole current U.S. recommendation.

Which situations can change the plan?

The guidance highlights the escalation phase, significant digestive symptoms, higher doses associated with more gastrointestinal effects, and other conditions that delay stomach emptying. The team may consider delaying an elective procedure, modifying pre-procedure intake, using gastric ultrasound, or changing the anesthesia plan.¹

A liquid-only period is one possible team-directed measure, not a fasting instruction that readers should apply independently. Ask the facility to specify permitted liquids, timing, other medicines, and any diabetes-monitoring plan. Colonoscopy preparation and instructions for a different operation are not interchangeable.

Report constipation, vomiting, or a recent symptom change even if it seems unrelated to the appointment. Our constipation guide and burping guide distinguish symptoms from diagnoses; neither can determine whether your stomach is empty on procedure day.

What a 2026 randomized trial adds

The OCULUS trial studied people taking GLP-1 or GLP-1/GIP medicines before elective upper endoscopy. At its preplanned interim analysis of 60 participants, clinically significant residual gastric volume occurred in 25.0% of those continuing treatment versus 3.1% of those holding one dose. The trial stopped early after meeting its prespecified boundary.⁶

That is evidence about a defined retained-content outcome in a small endoscopy trial. It is not a 25% aspiration rate. The trial did not show a corresponding increase in aspiration-related adverse events, and it excluded people scheduled for general anesthesia and certain higher-risk conditions.

The result adds information for procedural teams; it does not establish one self-directed hold rule for every drug, operation, or patient. Small numbers and early stopping also limit precision. “Most can continue” should not become “the medicine never affects procedural risk.”

Make the medication list specific

Give the team the actual brand, molecule, formulation, dose, usual schedule, and last administration date. Include oral products and compounded preparations, not just weekly injections. Bring other medicines and supplements, particularly diabetes treatments that may need coordinated planning if intake or treatment changes.

Our interaction guide explains why the exact product matters. If one team tells you to pause while another says to continue, ask them to reconcile the instructions before the procedure instead of choosing whichever answer is more convenient.

Urgent procedures and restarting need their own plan

Do not delay emergency care to complete a medication-free interval. Tell the team what you have taken; emergency management differs from planning an elective appointment.⁵

Before discharge or a planned interruption, ask who will provide restart instructions, what to do if nausea or reduced intake persists, and whether missed treatment affects other medicines. Do not assume returning immediately to the previous dose is appropriate after any length of interruption. Our stopping-treatment guide explains continuity questions without supplying a restart regimen.

Keep the final instructions in writing. A safe plan is coordinated around your procedure and medical needs, with a contact for unresolved questions—not copied from a general medication chart.